Mark W. Frohlich

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. Kantoff, Celestia S. Higano, Neal D. Shore et al. · New England Journal of Medicine · 2010 · 5.5K citations · Full text

Medicine, Oncology, Urology +14

Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

Celestia S. Higano, Paul F. Schellhammer, Eric J. Small et al. · Cancer · 2009 · 812 citations

Medicine, Immunology, Oncology +15

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

Nadeem A. Sheikh, Daniel P. Petrylak, Philip W. Kantoff et al. · Cancer Immunology Immunotherapy · 2012 · 264 citations · Full text

Medicine, Immunology, Oncology +17

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

Paul F. Schellhammer, Gerald W. Chodak, James B. Whitmore et al. · Urology · 2013 · 242 citations

Medicine, Oncology, Urology +14

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

Lawrence Fong, Peter R. Carroll, Vivian Weinberg et al. · JNCI Journal of the National Cancer Institute · 2014 · 210 citations · Full text

Medicine, Immunology, Oncology +17